Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in ...
Sign up now to get our FREE breaking news coverage delivered right to your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results